Comparison of uremic pruritus between patients undergoing hemodialysis and peritoneal dialysis  by Min, Ji-Won et al.
Kidney Res Clin Pract 35 (2016) 107e113Kidney Research and Clinical Practice
journal homepage: http: / /www.krcp-ksn.com
Contents l ists avai lable at ScienceDirectOriginal ArticleComparison of uremic pruritus between patients undergoing
hemodialysis and peritoneal dialysis
Ji-Won Min 1, Su-Hyun Kim 2, Young Ok Kim 1, Dong Chan Jin 1, Ho Chul Song 1,
Euy Jin Choi 1, Yong-Lim Kim 3, Yon-Su Kim 4, Shin-Wook Kang 5, Nam-Ho Kim 6,
Chul Woo Yang 1, Yong Kyun Kim 1,*
1 Division of Nephrology, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
2 Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea
3 Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
4 Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea
5 Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Korea
6 Department of Internal Medicine, Chonnam National University Medical School, Gwangju, KoreaArticle history:
Received 4 November 2015
Received in revised form
10 January 2016
Accepted 7 February 2016
Available online 21 February 2016
Keywords:
Hemodialysis
Peritoneal dialysis
Uremic pruritus* Corresponding author. Division of Nephrolo
Seoul, Korea.
E-mail address: drkimyk@catholic.ac.kr (YK Kim
http://dx.doi.org/10.1016/j.krcp.2016.02.002
2211-9132/Copyright © 2016. The Korean Socie
(http://creativecommons.org/licenses/by-nc-ndA B S T R A C T
Background: Uremic pruritus is a common, but unpleasant, complication of end-
stage renal disease. The uremic burden may differ between hemodialysis (HD) and
peritoneal dialysis (PD) patients. This difference may also change the clinical char-
acteristics of uremic pruritus between the 2 modalities. In this study, we investi-
gated the uremic pruritus between patients on HD and PD.
Methods: A total of 425 HD and 223 PD patients from the Clinical Research Center
registry in Korea were included. Patients were assessed for pruritus intensity,
scratching activity, pruritus distribution, and frequency of pruritus-related sleep
disturbance using the visual analog scale and questionnaire.
Results: The prevalence of uremic pruritus was higher in PD patients than that in
HD patients (62.6% vs. 48.3%, P ¼ 0.001). In the multivariable logistic analysis, PD
treatment was signiﬁcantly associated with the prevalence of uremic pruritus (odds
ratio, 1.76; 95% conﬁdence interval, 1.20e2.57, P ¼ 0.004) after adjustment for
clinical variables. The visual analog scale score, representing a subjective intensity of
itchiness, was signiﬁcantly higher in PD patients (PD 2.11± 2.32 vs. HD 1.65± 2.28,
P ¼ 0.013) compared with HD patients. The intensity of uremic pruritus was inde-
pendently related with serum albumin levels (b ¼ e0.143, P ¼ 0.006) in HD patients
and total weekly Kt/V (b ¼ e0.176, P ¼ 0.028) in PD patients.
Conclusion: Our data demonstrate the difference in prevalence, intensity, and risk
factors of uremic pruritus between HD and PD patients. These ﬁndings suggest that
careful consideration for uremic pruritus might be needed in end-stage renal dis-
ease patients according to the dialysis modality.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).gy, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea,
).
ty of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-ND license
/4.0/).
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Uremic pruritus is a common and disabling complica-
tion that affects the quality of life in end-stage renal dis-
ease (ESRD) patients undergoing hemodialysis (HD) and
peritoneal dialysis (PD) [1e5]. The prevalence of uremic
pruritus has been reported from 22% to 84% in HD patients
[2e9].
The degrees of intensity and the spatial distribution of
uremic pruritus are inﬂuenced by multiple factors and vary
over time [3,6]. Although its pathogenesis is not well under-
stood, factors such as uremic burden (i.e., increased inﬂam-
mation), secondary hyperparathyroidism, iron-deﬁciency
anemia, neuropathy, and neurophysiological factors or allergic
sensitization may contribute to the development of uremic
pruritus [2e9]. Severe uremic pruritus negatively affects the
quality of life and is associated with a poor outcome in HD
patients [3].
The uremic burden may differ between HD and PD patients
[10], which may make a difference in clinical characteristics of
uremic pruritus between patients on HD and PD. Therefore, it
may be postulated that clinical characteristics of uremic pru-
ritus may be different between patients on HD and PD. A pre-
vious study reported a higher prevalence of uremic pruritus in
PD patients than in HD patients [11]. However, the study is
limited by a relatively small sample size.
In this study, we determined the differences in the preva-
lence and the clinical characteristics of uremic pruritus in pa-
tients with uremic pruritus undergoing PD and HD from the
Clinical Research Center registry for ESRD, a multicenter cohort
study in Korea.
Methods
Study population
Patients were selected from the Clinical Research Center
registry for ESRD, which is a multicenter, observational,
prospective cohort study on patients with ESRD in Korea.
Adult patients (aged > 18 years) with ESRD undergoing PD or
HD were included from 31 medical centers in Korea. The
study was performed between April 2009 and April 2015.
Only patients who had completed a questionnaire about
uremic pruritus were included. A total of 648 patients from 9
medical centers were included in the ﬁnal analysis. Of these,
425 patients were undergoing HD and 223 were undergoing
PD. Demographic and clinical data were collected at enroll-
ment. The study protocol was approved by the medical
ethics committees of all participating hospitals. Written
informed consent was obtained from all patients before
inclusion.
Pruritus assessment
A survey was used to measure uremic pruritus by 2 scoring
systems. A detailed scoring system modiﬁed by Pauli-Magnus
[12] was used to assess the characteristics of pruritus including
intensity, scratching activity, pruritus distribution, and the
frequency of pruritus-related sleep disturbances. The visual
analog scale (VAS) was used to assess the subjective intensity of
itchiness. A survey was done by trained investigators. These
parameters were graded as follows:1. Pruritus scoring system modiﬁed by Pauli-Magnus
Severity: A slight itchy sensationwithout the need to scratch
received 1 point. The necessity to scratch, but in the absence of
excoriations received 2 points. Scratching accompanied by
excoriation received 4 points. Finally, pruritus causing total
restlessness received 5 points.
Distribution: Itching at fewer than 2 locations received 1
point, at 2 locations 2 points, and generalized itching 3 points.
The scores for pruritus severity and distribution were recor-
ded and multiplied separately based on those from the
morning and afternoon. A maximum of 30 points could be
achieved.
Sleep disturbance: Each arousal from sleep due to itching
received 2 points (maximum 10 points). Every nighttime
scratching episode that led to excoriations received 1 point
(maximum 5 points). The ﬁnal score was obtained by adding
the sleep disturbance score and the severityedistribution
product. There was a maximum of 45 points.
2. Visual Analog Scale
In addition to the pruritus scoring systemmodiﬁed by Pauli-
Magnus, we assessed uremic pruritus using the VAS. The VAS
has been previously used to assess itching intensity in clinical
trials [13,14]. Patients were asked to grade their itching in-
tensity on a 10-cm VAS (0¼ no pruritus to 10¼ unbearable
pruritus). Patients without uremic pruritus were deﬁned by a
score of 0.
Data collection
The following baseline demographic and clinical data were
recorded: age, sex, height,weight, bodymass index (BMI), causes
of ESRD, comorbidities, systolic blood pressure (BP), diastolic BP,
laboratory investigations, and therapeutic characteristics. Blood
samples were drawn to measure serum hemoglobin, albumin,
creatinine, blood urea nitrogen, potassium, total cholesterol,
calcium, phosphorous, high-sensitivity C-reactive protein, intact
parathyroid hormone, and b2-microglobulin.
Statistical analysis
Continuous variables with normal distributions are
expressed as means± standard deviations. Those without
normal distributions are presented as medians and interquartile
ranges. Student t tests were used to compare continuous vari-
ables. Categorical variables are presented as numbers with
percentages. The Pearson chi-square test was used to compare
the categorical variables. Univariate and multivariate logistic
regression analyses were used to assess the clinical factors
associated with uremic pruritus in HD patients. Multivariate
logistic regression analysis was adjusted for signiﬁcant or nearly
signiﬁcant (P < 0.05) predictors of uremic pruritus in univariate
logistic regression analysis including BMI and serum albumin
levels. To achieve adequate confounder control, important
covariates known to be inﬂuential based on prior studies and
clinical insight were retained in the multivariate logistic
regression model, regardless of their statistical signiﬁcance.
These covariates included age, sex, and diabetes mellitus (DM).
Survival curves were estimated by the KaplaneMeier
method and compared by the log-rank test according to the
presence of uremic pruritus. A P value < 0.05 was considered
Table 2. Prevalence and characteristics of uremic pruritus by dialysis
modality
Characteristics Hemodialysis
(n¼ 425)
Peritoneal
dialysis
(n¼ 223)
P
Prevalence of pruritus (%)
Morning 44.3 57.7 0.002
Afternoon 47.0 62.2 < 0.001
Throughout the day 48.3 62.6 0.001
Characteristics of uremic pruritus
Detailed score (Pauli-Magnus scoring system)
Severity
Morning 1.32± 0.82 1.29± 0.77 0.654
Afternoon 1.46± 0.96 1.50± 1.02 0.288
Distribution
Morning 1.17± 0.61 1.19± 0.65 0.790
Afternoon 1.17± 0.62 1.23± 0.68 0.272
Sleep disturbance
Frequency of waking
from sleep
0.24± 0.91 0.23± 0.74 0.925
Frequency of scratching
during sleep
0.19± 0.96 0.12± 0.56 0.332
Total score by measuring
system
4.54± 6.35 4.52± 5.35 0.356
VAS scoring system
Morning 1.40± 2.10 1.73± 2.06 0.057
Afternoon 1.90± 2.66 2.51± 2.73 0.006
Average 1.65± 2.28 2.11± 2.32 0.013
Continuous variables are presented by means± SD.
VAS, visual analog scale.
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using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Baseline characteristics of the study population according to
dialysis modality are shown in Table 1. PD patients were older
than HD patients. PD patients had higher BMI, diastolic BP,
serum levels of creatinine, phosphorus, calciumephosphorus
product, intact parathyroid hormone, b2-microglobulin, and
ferritin than HD patients. There was a lower prevalence of
DM in the PD patients than in the HD patients. In addition, the
systolic BP, serum albumin levels, and serum high-sensitivity
C-reactive protein levels were lower in the PD patients than
those in the HD patients. There were no signiﬁcant differences
in sex, duration of dialysis therapy, fasting blood glucose, he-
moglobin, blood urea nitrogen, serum calcium, total cholesterol
levels, or use of medications such as calcium-containing or
nonecalcium-containing phosphate binders, active vitamin D
compounds, and calcimimetics between the HD and PD
patients.
Prevalence and characteristics of uremic pruritus
Table 2 shows the prevalence and characteristics of uremic
pruritus according to the dialysis modality. There was a higher
prevalence of uremic pruritus throughout the day, and it was
higher in the PD patients than in the HD patients (62.6% vs.
48.3%, P ¼ 0.001). Uremic pruritus was more prevalent in PD
patients than in HD patients in the morning (62.2% vs. 47.0%,
P ¼ 0.002) and afternoon (57.7% vs. 44.3%, P < 0.001).Table 1. Baseline characteristics of patients
Characteristics Hemodialysis
Age (y) 58.0± 1
Male 237 (55
Body mass index (kg/m2) 22.6± 3
Diabetes mellitus 215 (55
Duration of dialysis therapy (mo) 50 (29
Systolic BP (mmHg) 144.0± 2
Diastolic BP (mmHg) 75.0± 1
Fasting blood glucose (mg/dL) 146.0± 7
BUN (mg/dL) 66.0± 2
Serum creatinine (mg/dL) 9.0± 2
Hemoglobin (g/dL) 10.3± 1
Serum albumin (g/dL) 3.7± 0
Serum calcium (mg/dL) 8.6± 1
Serum phosphorus (mg/dL) 5.0± 1
Serum calciumephosphorus product (mg2/dL2) 42.7± 1
Serum total cholesterol (mg/dL) 141.0± 6
Serum intact PTH (pg/mL) 147 (65
b2-microglobulin (mg/dL) 248 (13
Serum ferritin (mg/dL) 62 (45
hsCRP (mg/dL) 0.13 (0.
Using high-ﬂux dialysis 116 (27
Single-pool Kt/V 1.6± 0
Total weekly Kt/V
Medication
Calcitriol or vitamin D analogues 100 (24
Calcium-containing phosphorus binder 249 (59
Nonecalcium-containing phosphorus binders 40 (9)
Values for continuous variables are given asmean± SD and variableswithout a
categorical variables are given as n (%).
BP, blood pressure; BUN, blood urea nitrogen; hsCRP, high-sensitivity C-reactivWe also assessed the clinical characteristics of uremic pru-
ritus according to the dialysis modality. There were no signiﬁ-
cant differences in pruritus intensity, scratching activity,
pruritus distribution, or frequency of pruritus-related sleep
disturbances between PD and HD patients.(n¼ 425) Peritoneal dialysis (n¼ 223) P
2.0 53.0± 11.0 < 0.001
.8) 127 (59.2) 0.402
.5 23.9± 3.4 < 0.001
.0) 91 (41.2) 0.001
e83) 55 (34e86) 0.377
1.0 133.0± 22.0 < 0.001
4.0 80.0± 12.0 < 0.001
2.0 135.0± 75.0 0.082
4.0 63.0± 24.0 0.169
.9 10.2± 3.7 < 0.001
.4 10.2± 1.5 0.373
.5 3.6± 0.4 < 0.001
.0 8.5± 0.9 0.326
.0 5.3± 1.5 0.016
3.6 45.3± 13.6 0.027
5.0 150.0± 75.0 0.191
e273) 222 (110e412) < 0.001
5e414) 287 (137e569) 0.043
e78) 67 (52e93) 0.010
00e1.57) 0 (0e0.02) < 0.001
.3)
.5
3.1± 1.3
) 53 (24) 0.946
) 116 (52) 0.109
16 (7) 0.336
normal distribution are given asmedian and interquartile range; values for
e protein; PTH, parathyroid hormone.
Figure 1. Distribution of patients in each range of VAS scores in HD and PD patients. VAS in the morning (A) and VAS in the afternoon (B) are
shown. HD, hemodialysis; PD, peritoneal dialysis; VAS, visual analog scale.
Kidney Res Clin Pract 35 (2016) 107e113110The VAS scorewas signiﬁcantly higher in PD patients than it
was in HD patients, especially in the afternoon (average, PD
2.11 ± 2.32 vs. HD 1.65± 2.28, P ¼ 0.013; afternoon, PD
2.51± 2.73 vs. HD 1.90± 2.66, P ¼ 0.006; Table 2). Fig. 1 shows
the distribution of patients with each range of VAS scores
in the patients with HD and PD. There are few PD and HD
patients with severe uremic pruritus (VAS score > 7) in
the morning. PD patients with moderate-to-severe uremicTable 3. Logistic regression analysis for predicting prevalence of uremic
Risk factors Un
Odds ratio (95%
PD (vs. HD) 1.79 (1.28e2.49
Age (per 10 y) 1.01 (0.99e1.02
Sex (male vs. female) 1.05 (0.77e1.44
Body mass index (per 1 kg/m2) 1.07 (1.02e1.12
DM (vs. non-DM) 1.11 (0.81e1.53
Duration of dialysis (per 1 mo)
Systolic BP (per 10 mmHg) 1.01 (1.00e1.01
Fasting blood glucose (mg/dL) 1.00 (1.00e1.00
HbA1c in patients with DM (per 1%) 1.03 (0.99e1.08
BUN (per 1 mg/dL) 1.00 (0.99e1.01
Serum creatinine (per 1 mg/dL)
Hemoglobin (per 1 g/dL) 1.06 (0.96e1.19
Serum albumin (every 1 mg/dL) 0.69 (0.48e1.00
Serum calcium (per 1 mg/dL) 0.98 (0.82e1.16
Serum phosphorus (per 1 mg/dL) 1.02 (0.92e1.13
Serum calciumephosphorus product
(per 1 mg2/dL2)
1.00 (0.99e1.01
Serum alkaline phosphatase (per 1 mg/dL)
Total cholesterol (per 1 mg/dL) 1.00 (1.00e1.01
iPTH (per 100 pg/mL) 1.00 (0.98e1.03
b2-microglobulin (per 1 mg/dL) 1.00 (1.00e1.00
Serum ferritin (per 1 mg/dL) 1.00 (0.99e1.01
hsCRP (mg/dL) 1.00 (0.99e1.01
spKt/V < 1.2 in HD patients (vs. spKt/V  1.2) 1.07 (0.41e2.76
Total weekly Kt/V < 1.7 in PD patients
(vs. total weekly Kt/V  1.7)
1.89 (0.44e8.16
Use of calcitriol or vitamin D analogues
(vs. nonuser)
1.17 (0.81e1.68
Use of calcium-containing phosphorus
binder (vs. nonuser)
1.11 (0.81e1.52
Use of nonecalcium-containing phosphorus
binders (vs. nonuser)
1.10 (0.63e1.90
BP, blood pressure; BUN, blood urea nitrogen; CI, conﬁdence interval; DM, dia
sensitivity C-reactive protein; iPTH, intact parathyroid hormone; PD, peritonpruritus (VAS score  4) were more common in the afternoon
compared with HD patients (Fig. 1B).
Determinants of prevalence and intensity of uremic pruritus
First, we evaluated the clinical parameters to predict the
prevalence of uremic pruritus. Table 3 shows the clinical and
laboratory risk factors that inﬂuence the prevalence of uremicpruritus
ivariate Multivariate
CI) P Odds ratio (95% CI) P
) 0.001 1.76 (1.20e2.57) 0.004
) 0.429 1.01 (0.99e1.02) 0.412
) 0.746 1.00 (0.71e1.41) 0.989
) 0.006 1.06 (1.01e1.12) 0.017
) 0.512 1.07 (0.76e1.52) 0.695
) 0.211
) 0.221
) 0.155
) 0.607
) 0.263
) 0.050 0.77 (0.52e1.14) 0.190
) 0.779
) 0.708
) 0.862
) 0.236
) 0.769
) 0.448
) 0.917
) 0.795
) 0.892
) 0.396
) 0.401
) 0.508
) 0.741
betes mellitus; HbA1c, hemoglobin A1c; HD, hemodialysis; hsCRP, high-
eal dialysis; spKt/V, single-pool Kt/V.
Table 4. Spearman's correlation between the intensity of uremic
pruritus using VAS and clinical parameters in HD and PD patients
Clinical parameters HD PD
r P r P
Age (per 10 y) 0.032 0.506 0.096 0.156
Duration of dialysis (per 1 mo) e0.023 0.632 0.139 0.040
Body mass index (per 1 kg/m2) 0.070 0.172 0.063 0.356
Systolic BP (per 10 mmHg) 0.070 0.170 0.137 0.047
Fasting blood glucose (mg/dL) e0.015 0.763 e0.043 0.523
HbA1c in patients with DM (per 1%) 0.074 0.172 e0.072 0.287
BUN (per 1 mg/dL) 0.004 0.931 e0.022 0.753
Serum creatinine (per 1 mg/dL) 0.030 0.557 0.088 0.198
Hemoglobin (per 1 g/dL) e0.032 0.525 0.106 0.116
Serum albumin (every 1 mg/dL) e0.156 0.002 e0.022 0.754
Serum calcium (per 1 mg/dL) e0.081 0.111 0.096 0.173
Serum phosphorus (per 1 mg/dL) 0.022 0.665 0.014 0.841
Total cholesterol (per 1 mg/dL) e0.014 0.783 0.153 0.036
iPTH (per 100 pg/mL) 0.168 0.143 0.114 0.514
b2-microglobulin (per 1 mg/dL) 0.008 0.876 e0.091 0.321
Serum ferritin (per 1 mg/dL) e0.011 0.837 e0.096 0.247
hsCRP (mg/dL) 0.032 0.517 e0.096 0.307
spKt/V in HD patients e0.048 0.376
Total weekly Kt/V in PD patients e0.206 0.002
BP, blood pressure; BUN, blood urea nitrogen; DM, diabetic mellitus;
HbA1c; hemoglobin A1c; HD, hemodialysis; hsCRP, high-sensitivity C-
reactive protein; PD, peritoneal dialysis; PTH, intact parathyroid hor-
mone; spKt/V, single-pool Kt/V; VAS, visual analog scale.
Table 5. Multivariate linear regression analyses for intensity of ure-
mic pruritus using VAS in HD and PD patients
Clinical parameters HD PD
b coefﬁcient P b coefﬁcient P
Age (per 10 y) e0.062 0.244 0.108 0.172
Sex (male) e0.003 0.950 0.086 0.274
Body mass index (per 1 kg/m2) 0.030 0.562 0.093 0.246
DM e0.097 0.071 e0.041 0.620
Duration of dialysis (per 1 mo) 0.010 0.845 e0.026 0.755
Systolic BP (per 10 mmHg) 0.005 0.924 0.093 0.231
Fasting blood glucose, mg/dL e0.102 0.069 e0.039 0.666
BUN (per 1 mg/dL) 0.030 0.562 0.051 0.545
Serum creatinine (per 1 mg/dL) 0.014 0.785 0.219 0.026
Hemoglobin (per 1 g/dL) 0.044 0.440 0.102 0.205
Serum albumin (every 1 mg/dL) e0.143 0.006 e0.064 0.443
Serum calcium (per 1 mg/dL) e0.006 0.921 0.056 0.523
Serum phosphorus
(per 1 mg/dL)
0.037 0.482 0.120 0.163
Total cholesterol (per 1 mg/dL) 0.012 0.819 0.027 0.732
iPTH (per 100 pg/mL) 0.095 0.436 e0.447 0.181
b2-microglobulin (per 1 mg/dL) e0.060 0.269 0.001 0.996
Serum ferritin (per 1 mg/dL) 0.017 0.758 e0.046 0.629
hsCRP (mg/dL) e0.029 0.589 0.054 0.481
spKt/V in HD patients e0.021 0.701
Total weekly Kt/V in
PD patients
e0.176 0.028
Adjusted for age, sex, DM, systolic BP, and serum albumin levels in HD
patients.
Adjusted for age, sex, DM, duration of dialysis, systolic BP, serum total
cholesterol levels, and total weekly Kt/V in PD patients.
BP, blood pressure; BUN, blood urea nitrogen; DM, diabetic mellitus;
HbA1c, hemoglobin A1c; HD, hemodialysis; hsCRP, high-sensitivity C-
reactive protein; iPTH, intact parathyroid hormone; PD, peritoneal
dialysis; spKt/V, single-pool Kt/V; VAS, visual analogue scale.
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analysis, PD treatment [odds ratio (OR), 1.79; 95% conﬁdence
interval (CI), 1.28e2.49; P ¼ 0.001] and BMI (OR, 1.07; 95% CI,
1.02e1.12; P ¼ 0.006) signiﬁcantly inﬂuenced the prevalence of
uremic pruritus. In multivariable logistic analysis, PD treatment
and BMI were signiﬁcant independent risk factors for the
prevalence of uremic pruritus (OR, 1.76; 95% CI, 1.20e2.57; P ¼
0.004 and OR, 1.06; 95% CI, 1.01e1.12; P ¼ 0.017, respectively)
after adjustment for age, sex, BMI, dialysis modality, DM, and
serum albumin level.
Next, we determined the clinical parameters associatedwith
the intensity of uremic pruritus according to dialysis modality.
Table 4 shows the Spearman correlation between the intensity
of uremic pruritus and clinical parameters in HD and PD pa-
tients. The intensity of uremic pruritus was negatively corre-
lated with serum albumin levels in HD patients. In PD patients,
the intensity of uremic pruritus was negatively correlated with
total weekly Kt/V and positively correlated with duration of
dialysis, systolic BP, and serum total cholesterol levels.
To determine the independent predictor for the intensity of
uremic pruritus, we performed multiple linear regression
analysis using the model including age, sex, DM, and all uni-
variate correlates of the intensity of uremic pruritus (Table 5).
In HD patients, serum albumin levels (b ¼ e0.143, P ¼ 0.006)
maintained an independent relationship with the intensity of
uremic pruritus, whereas in PD patients, total weekly Kt/V (b ¼
e0.176, P ¼ 0.028) was independently associated with the
subjective intensity of uremic pruritus.
Uremic pruritus and all-cause mortality
To determine the clinical impact of uremic pruritus in HD
and PD patients, we performed the survival analysis. We
divided the patients into 4 groups according to the intensity of
uremic pruritus by using VAS as follows: group 1, patients
with no pruritus (n ¼ 304); group 2, mild pruritus with
VAS scores < 4.0 (n¼ 207); group 3, moderate pruritus withVAS score 4.0e6.9 (n¼ 106); and group 4, severe pruritus
with VAS score  7 (n¼ 31). The KaplaneMeier survival
analysis showed that there was no signiﬁcant difference in all-
cause mortality among the groups in whole cohort including
HD and PD patients (P ¼ 0.249, log-rank test) as well as in HD
patients (P ¼ 0.055, log-rank test) and PD patients (P ¼ 0.922,
log-rank test).
Discussion
In this study, we showed that there was a higher prevalence
of uremic pruritus in PD patients than therewas in HD patients.
Furthermore, the subjective intensity of itchiness (assessed by
VAS)was higher in PD patients than it was in HDpatients. These
ﬁndings indicate that prevalence and clinical characteristics of
uremic pruritus differ according to the dialysis modality.
The prevalence of uremic pruritus in HD patients has been
previously reported. However, there are limited data regarding
uremic pruritus in PD patients. In their study of 113 continuous
ambulatory peritoneal dialysis patients and 76 HD patients,
Balaskas et al [11] found that the prevalence of uremic pruritus
was 62% in continuous ambulatory peritoneal dialysis and 54%
in HD. In this study, the prevalence of uremic pruritus over the
course of the whole day was 62.6% in PD patients and 48.3% in
HD patients. The PD patients had approximately 1.8-fold
increased risk of uremic pruritus than did the HD patients.
Another interesting ﬁnding of this study is the different
relationship between the intensity of uremic pruritus and
clinical parameters according to dialysis modality. In this study,
the intensity of uremic pruritus was negatively associated with
serum albumin levels in HD patients, which suggests the
Kidney Res Clin Pract 35 (2016) 107e113112impact of the serum albumin as a negative acute-phase protein
on uremic pruritus in HD patients [8]. Interestingly, in this
study, single-pool Kt/V was not related with the intensity of
uremic pruritus in HD patients, whereas total weekly Kt/V was
independently associated with the intensity of uremic pruritus
in PD patients. These ﬁndings are consistent with previous
studies [4,15]. Pisoni et al [15] reported that Kt/V did not show
any signiﬁcant relationship with pruritus in HD patients in
Dialysis Outcomes and Practice Patterns Study. Liakopoulos
et al [4] demonstrated the beneﬁcial effect of increased dialy-
zate volume on uremic symptoms in chronic PD patients. These
ﬁndings support the idea that adequate dialysis may be criti-
cally important in reducing the intensity of uremic pruritus in
PD patients.
One strength of this studywas its relatively large sample size
and multicenter design, which enhances the evidence of
prevalence of uremic pruritus.
Another strength of this study is that we assessed the ure-
mic pruritus by using a pruritus scoring system modiﬁed by
Pauli-Magnus [12] and the VAS. The detailed characteristics of
pruritus including intensity, scratching activity, pruritus dis-
tribution, and the frequency of pruritus-related sleep distur-
bances were assessed by Pauli-Magnus scoring system. The
subjective intensity of itchiness was assessed by VAS scoring
system. In this study, scratching activity, pruritus distribution,
and the frequency of pruritus-related sleep disturbances were
not signiﬁcantly different according to dialysis modality.
Interestingly, the VAS score was signiﬁcantly higher in PD pa-
tients than it was in HD patients, especially in the afternoon.
This ﬁnding suggests that PD patients have greater subjective
itch intensity than do HD patients (Table 2). However, the in-
tensity measured by VAS was not severe in general, and the
difference of VAS score between HD and PD patients was
relatively small (HD: 1.65± 2.28 vs. PD: 2.11± 2.32). Therefore,
clinical signiﬁcance of these ﬁndings needed to be cautiously
interpreted.
It is unclear why PD patients had a higher prevalence and
subjective intensity of uremic pruritus than did HD patients.
However, there are several potential explanations. Uremic
pruritus has been associated with the accumulation of middle
molecular weight uremic toxins such as b2-microglobulin [2,9].
Dialysis clearance of b2-microglobulin with HD treatment us-
ing a high-ﬂuxmembrane has been reported to bemuch higher
than with PD treatment [16e18]. High-ﬂux dialyzers are now
widely used in clinical practice. The present study included
approximately 30% of HD patients using the high-ﬂux dialyzer.
In concordance with this idea, PD patients had signiﬁcantly
higher serum levels of b2-microglobulin than did HD patients
in this study. Therefore, it is possible that increased accumu-
lation of uremic toxins in PD patients may contribute to the
higher prevalence and intensity of uremic pruritus compared to
that in HD patients.
For the association between uremic pruritus and clinical
outcomes in ESRD patients, Narita et al [3] reported that severe
uremic pruritus (VAS score > 7) is associated with clinical poor
outcomes including mortality in chronic HD patients. However,
in this study, the presence of uremic pruritus was not associ-
ated with all-cause mortality not only in HD patients but also in
PD patients. It may be due to the differences in the study
population. In this study, the percentage of patients with severe
uremic pruritus was much lower (4.5% in HD patients and 5.4%
in PD patients) than that of the previous study (25.6% in HDpatients) [3], which may have resulted in the discrepancy be-
tween the studies. Despite the nonsigniﬁcant association be-
tween uremic pruritus and all-cause mortality in this study,
uremic pruritus might be considered as an important risk factor
for poor clinical outcomes in consideration of the relationship
between uremic pruritus and quality of life or morality in ESRD
patients from previous studies [3,6].
Our study has several limitations. First, the design of our
study was not a randomized controlled study but rather was an
observational study. The choice of dialysis modality may have
been inﬂuenced by clinicians and patients. Therefore, it is
difﬁcult to infer causality between dialysis modality and uremic
pruritus. In addition, despite the study's multicenter nature, all
patients were of Asian descent. Therefore, our results may not
be generalizable to other ethnic groups with ESRD. Second, dry
skinmay be one of themajor factors to exacerbate pruritus [19].
Unfortunately, it was not assessed in this study. Third, chronic
inﬂammation had signiﬁcant impact on uremic pruritus and
mortality in dialysis patients [3]. To clarify the relationship
between uremic pruritus and mortality, the patients with
chronic inﬂammatory diseases may need to be excluded.
However, they were not excluded at the time of enrollment in
this study.
In conclusion, our data demonstrate the differences in
prevalence, intensity, and risk factors of uremic pruritus be-
tween HD and PD patients. These ﬁndings suggest that careful
consideration for uremic pruritus might be needed in ESRD
patients according to the dialysis modality.
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